ERBB2 and breast cancer: In this respect, while in the absence of trastuzumab NC including anthracyclines still induces superior outcomes [25], a recent paper by Guiu and colleagues [26] reported competitive results in terms of DFS and OS in locally advanced HER2-positive BC patients treated with anthracycline-free trastuzumab-based NC.